TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00737646

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: No intervention will be conducted in this arm of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-focused intervention
Description: The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff. The provider training sessions will include the presentation of CRC screening statistics and information, and will be heavily interactive and skills-based. The provider training sessions will also focus on the provision of tools for improving clinical staff- and clinician-patient interactions about CRC screening and for office system changes/improvements to identify eligible patients and to track screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic- and patient-focused
Description: This arm will combine the clinic-focused intervention and the patient-focused intervention. The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff as described in Arm 2. The patient-focused intervention includes sending a CRC screening education packet (CDC-developed educational text tailored for use within the study sites), accompanied by a letter from the patient's physician, to patients meeting study inclusion criteria.
Study: NCT01917383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabodenoson
Description: Ophthalmic eye drop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Ophthalmic eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: Ophthalmic eye drop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol
Description: Ophthalmic eye drop
Study: NCT02888106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex B
Description: Lyophilised powder for solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex B
Description: Lyophilised powder for solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex B
Description: Lyophilised powder for solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex B
Description: Lyophilised powder for solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex B
Description: Lyophilised powder for solution for subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG IFN alfa-2a
Description: solution for subcutaneous injection, once per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG IFN alfa-2a
Description: solution for subcutaneous injection, once per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG IFN alfa-2a
Description: solution for subcutaneous injection, once per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG IFN alfa-2a
Description: solution for subcutaneous injection, once per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Film-coated tablets, 300 mg, per os, once daily
Study: NCT04618146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: intrathecal low dose morphine for early return to normal activity without opioid related complications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: intrathecal low dose morphine for early return to normal activity without opioid related complications.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: intrathecal bupivacaine 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: intrathecal bupivacaine 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: intrathecal bupivacaine 0.5%
Study: NCT02306681

Intervention type: OTHER
Intervention: No treatment given
Description: This study comprises of a two-part SAQ (Self-Assessment Questionnaire). Paired responses to SAQ1 and SAQ2 will be used to estimate the differences in the frequency of hypoglycaemic episodes between the retrospective and prospective periods.
Study: NCT04077021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCW702
Description: Investigational immunotherapy for prostate cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCW702
Description: Investigational immunotherapy for prostate cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCW702
Description: Investigational immunotherapy for prostate cancer
Study: NCT03744104

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine B
Description: 0.5 mL, intramuscular, one dose
Study: NCT02282852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless Capsule Endoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetically steerable capsule endoscopy
Study: NCT04976985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Therapy (OMT)
Description: Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic physicians receive special training in the musculoskeletal system to detect somatic dysfunction. Osteopathic physicians then move a patient's muscles and joints using techniques that include stretching, gentle pressure and resistance to improve muscle tonicity, treat structural abnormalities, relieve joint restriction, and decrease activation of the pain proprioception pathway.~OMT Standardized Protocol A:~1. Occipital- Alanto release~2. Muscle energy and soft tissue to mid trapezius muscle~3. Muscle energy to cervical spine in all three planes of flexion/extension, rotation and side bending~4. Screening for tender points of C2-C6 at transverse and spinous processes and treatment with counterstain if tender point identified~5. Soft tissue to cervical paraspinal muscles~6. Myo-fascial release of frontal forehead~7. CV4 cranial technique

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Receiving standard of care for migraine headaches with pharmacological medications, with no more than two prophylactic medications during the study period. Participants may also take abortive migraine medications.
Study: NCT03191617

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human milk fortifier
Description: Fortification of breastmilk with liquid human milk fortifier in premature infants

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human milk fortifier
Description: Fortification of breastmilk with liquid human milk fortifier in premature infants
Study: NCT00900978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7 valent pneumococcal conjugate vaccine (7v-PCV) - Prevenar
Description: The 7v-PCV will be given to children below 2 years of age. Nasopharyngeal swabs will be taken from the children before vaccination and after finishing the vaccination. The vaccine will be given in a 2+1 scheme.
Study: NCT02478008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardiAQ TMVI System (Transapical DS)
Study: NCT00049023

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 90Y-DOTA-tyr3-OCTREOTIDE
Study: NCT02153268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Arm - Liposuction procedure and BonoFill transplantation will be done for all subjects on study
Description: Liposuction - will be performed on Visit 2, BonoFill will be based on subject's autologous Human Adipose Tissue Derived Cells (HATDCs).~BonoFill Transplantation will be performed on Visit 6. BonoFill will be administrated to the subject in a single session at one tested cell dose.
Study: NCT05405010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stair climbing and descending for 1 minute
Description: Stair climbing and descending for 1 minute

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stair climbing and descending for 3 minutes
Description: Stair climbing and descending for 3 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Seated control
Description: Seated control
Study: NCT03527849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: The intervention will be an MBSR course.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: The intervention will be an MBSR course.
Study: NCT04569643

Intervention type: DIAGNOSTIC_TEST
Intervention: Actigraphy
Description: Participants will undergo overnight leg actigraphy at baseline. Leg movements will be recorded bilaterally by actigraphic method with two ankle-worn recorders.

Intervention type: DIAGNOSTIC_TEST
Intervention: Actigraphy
Description: Participants will undergo overnight leg actigraphy at baseline. Leg movements will be recorded bilaterally by actigraphic method with two ankle-worn recorders.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiorespiratory monitoring
Description: All participants will be scanned for presence of sleep-related breathing disorders with a portable monitoring device at baseline. The compact screening device will be attached to the patient's wrist during the night sleep.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiorespiratory monitoring
Description: All participants will be scanned for presence of sleep-related breathing disorders with a portable monitoring device at baseline. The compact screening device will be attached to the patient's wrist during the night sleep.
Study: NCT03527849

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Description: Propose to use an active control training, the Health Enhancement Program (HEP), an intervention designed to isolate mindfulness as a testable active ingredient. HEP and MBSR are structurally equivalent in that they share the same amount of in- and out-of class work time. The content of the HEP intervention meet the following criteria: (1) class activities match MBSR activities as closely as possible, (2) activities represent valid, active, therapeutic ingredients in their own right, and (3) these ingredients do not include mindfulness.
Study: NCT04400357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic pancreaticoduodenectomy
Description: Patients in this arm will undergo a pancreaticoduodenectomy with robotic-assisted techonology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open pancreaticoduodenectomy
Description: Patients in this arm will undergo an open pancreaticoduodenectomy which is the standard surgical approach.
Study: NCT04569643

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging
Description: All subjects will undergo brain MRI scanning at baseline and in 1-year follow-up. The imaging protocol will include axial T1, T2, T2\*, FLAIR and diffusion-weighted imaging scans that will be made on a 3-Tesla scanner.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging
Description: All subjects will undergo brain MRI scanning at baseline and in 1-year follow-up. The imaging protocol will include axial T1, T2, T2\*, FLAIR and diffusion-weighted imaging scans that will be made on a 3-Tesla scanner.

Intervention type: OTHER
Intervention: Assessment of cognitive function
Description: Assessment will take place at weeks 0 (baseline) and 52 (1 year follow-up). The neuropsychological protocol will be consist of Montreal Cognitive Assessment (MoCA), 12-word Verbal Memory Test, Benton Visual Retention Test, Frontal Assessment Battery, Trail Making Test (parts A and B), phonetic (as a part of the MoCA) and semantic verbal fluency assessment, Symbol Digit Modalities Test.

Intervention type: OTHER
Intervention: Assessment of cognitive function
Description: Assessment will take place at weeks 0 (baseline) and 52 (1 year follow-up). The neuropsychological protocol will be consist of Montreal Cognitive Assessment (MoCA), 12-word Verbal Memory Test, Benton Visual Retention Test, Frontal Assessment Battery, Trail Making Test (parts A and B), phonetic (as a part of the MoCA) and semantic verbal fluency assessment, Symbol Digit Modalities Test.
Study: NCT03111875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aggressive warming
Description: Patients will be pre-warming 30 minutes before induction of anesthesia and aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: routine thermal management
Description: A forced-air cover will be positioned but will not initially be activated. The warmer will be activated when core temperature decrease to 35.5°C.
Study: NCT03717688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entresto
Description: Single dose administration of Entrestro 194 mg sacubitril / 206 mg valstartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entresto
Description: Single dose administration of Entrestro 194 mg sacubitril / 206 mg valstartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: 2 x 100mg sitagliptin as single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: 2 x 100mg sitagliptin as single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: No treatment
Study: NCT01288235

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Description: 5 days a week
Study: NCT03855696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1113
Description: MG1113

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of MG1113
Description: Placebo of MG1113
Study: NCT01301807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Given PO
Study: NCT01145742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home health/primary care collaboration
Description: self-management support and telemonitoring of BP and blood glucose
Study: NCT00799201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone and Docusate
Description: Naloxone 6mg (15 mL) every 6 hours plus docusate sodium liquid 10 mL (100mg) every 12 hours
Study: NCT00896714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop anesthesia
Description: Propofol and Remifentanil are administered automatically using a closed-loop system
Study: NCT02774759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: Participant wears an accelerometer for 7 days before baseline visit to record activity levels, and again before their 6 month visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: Participant wears an accelerometer for 7 days before baseline visit to record activity levels, and again before their 6 month visit.
Study: NCT04569643

Intervention type: OTHER
Intervention: Sleep quality and mood questionnaires
Description: Self-reporting scales and questionnaires will be used at baseline to assess sleep quality, daytime functioning and mood. The protocol includes the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, the Geriatric Depression Scale.

Intervention type: OTHER
Intervention: Sleep quality and mood questionnaires
Description: Self-reporting scales and questionnaires will be used at baseline to assess sleep quality, daytime functioning and mood. The protocol includes the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, the Geriatric Depression Scale.
Study: NCT00536302

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Hydrolysate
Description: Collagen Hydrolysate solution 10 grams per day by mouth for 48 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution per day by mouth for 48 weeks.
Study: NCT01648686

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dental extraction
Description: 3 dental radiographies realised immediately, then 30 days, then 90 days after dental extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental extraction
Description: 3 dental radiographies realised immediately, then 30 days, then 90 days after dental extraction
Study: NCT01337583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dapivirine
Description: Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal Ring containing no drug substance
Study: NCT03920345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiZYTE
Description: Subjects can be treated either unilateral or bilateral, depending on their condition and the recommended treatment by the surgeon. The decision is a clinical one and is not influenced by the decision of whether to be included in the study or the subsequent outcomes and QoL analysis.
Study: NCT02559622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: 300 mg secukinumab

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo followed by 300 mg secukinumab

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo followed by 150 mg secukinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: 150 mg secukinumab
Study: NCT03678207

Intervention type: OTHER
Intervention: Anesthesiologist phone call
Description: Patients receiving ambulatory surgery with no prior diagnosis of hypertension but have elevated blood pressure prior to surgery. Patients will receive a phone call from a participating anesthesiologist 1-3 days after surgery notifying them of their high blood pressure and obtaining oral consent to participate in the study. Patients will receive reminders via mail about following up with their PCP.
Study: NCT01338441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: 4mg/Kg, IV during 20 min once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4mg/Kg, IV during 20 min once
Study: NCT01069432

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT01416818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaoyao Pill
Description: herb extracts,were received two times a day for 12 weeks without dose changing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupleurum+Ginkgo
Description: herb extracts, were received two times a day for 12 weeks without dose changing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo looked like herb extracts and were also received two times a day for 12 weeks without dose changing.
Study: NCT04256694

Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid Antigen Test for Group A Streptococcus
Description: Rapid strep tests will be performed by throat swab of healthy adult volunteers.
Study: NCT03576508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975-05
Description: 1 mg (2mL) IA injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qutenza
Description: 8% topical patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine (without epinephrine)
Description: 15 mL IA injection of 2% lidocaine (without epinephrine)
Study: NCT01337583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine
Study: NCT03883256

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow nasal cannula
Description: High flow nasal cannula is a device that delivered heated and humidified high flow gases to at or near body temperature to avoid drying and possible injury to the nasal mucosa. In this study, subjects perform a constant-load exercise test with high flow nasal cannula.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal cannula
Description: Nasal cannula is a device that delivered oxygen to patients. In this study, subjects perform a constant-load exercise test with nasal cannula.
Study: NCT02521506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verio Pattern Alert® activated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Verio Pattern Alert® deactivated
Study: NCT02854085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: The Art Therapy will consist of creating art pieces, narrating thoughts and inner experiences in relation to the pieces produced (2 sessions a month) and guided visits to the art gallery (one session a month) and art museum (one session a month); there will be 12 sessions weekly for 12 weeks. For the next 6 months, sessions will be fortnightly and consist of creating an art piece once a month alternating with a visit to either the art museum or gallery, once a month; there will be 12 sessions in 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Reminiscence Activity
Description: Music Reminiscence activity will be held weekly for 12 weeks and fortnightly for 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead. Session will entail listening and watching music videos and discussing activities, events and experiences related to the music; additional prompts such as photographs may be used to facilitate therapy.
Study: NCT01434277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Drops with Experimental Preservative
Description: Glycerin, Hypromellose, Polyethylene glycol 400 with experimental preservative PQ-42

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Drops with Experimental Preservative
Description: Glycerin, Hypromellose, Polyethylene glycol 400 with experimental preservative PQ-42
Study: NCT00112736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02656277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Tool

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information on Shoulder Dislocation